^
Association details:
| Biomarker: | HRD + BRCA wild-type |
|---|---|
| Cancer: | Triple Negative Breast Cancer |
| Drug: | carboplatin (Tubulin polymerization promoter) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Homologous recombination deficiency predicts the response to platinum-based neoadjuvant chemotherapy in early-stage triple-negative breast cancer patients: a systematic review and meta-analysis
Published date:
05/07/2022
Excerpt:
This meta-analysis aimed to determine the predictive value of HRD for the pCR rate in patients with triple-negative breast cancer (TNBC)....patients who received platinum (including carboplatin, cisplatin, or lobaplatin) alone or combined with other agents for NCT...Among HRD carriers, the pCR rate was higher in patients on platinum-based NCT than in those without platinum exposure (OR = 1.95, 95% CI = [1.17, 3.23], p = 0.01)....HRD carriers with wild-type BRCA had a significant advantage over non-HRD carriers on platinum-based NCT (OR = 3.64, 95% CI = [1.83, 7.21], p = 0.0002)....HRD is an effective predictor of increased pCR rates in platinum-based NCT, especially in wild-type BRCA patients.
DOI:
10.1177/17588359221096253
